Health Canada Approves Ozempic® (semaglutide injection) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) in Adults with Type 2 Diabetes
Ozempic® is indicated as an adjunct to diet, exercise, and standard of care to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke)… Read More




